{"id":810435,"date":"2025-02-07T08:04:18","date_gmt":"2025-02-07T13:04:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\/"},"modified":"2025-02-07T08:04:18","modified_gmt":"2025-02-07T13:04:18","slug":"processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\/","title":{"rendered":"Processa Pharmaceuticals to Present at the 2025 BIO CEO &amp; Investor Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <strong>HANOVER, Md., Feb.  07, 2025  (GLOBE NEWSWIRE) &#8212; Processa Pharmaceuticals, Inc. (Nasdaq: PCSA)<\/strong> (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced its participation in the 2025 BIO CEO &amp; Investor Conference being held February 10-11, 2025, at the New York Marriott Marquis.<\/p>\n<p align=\"justify\">Management will present a corporate overview on Tuesday, February 11 at 10:00 a.m. Eastern time in the Plymouth Room, and will hold one-on-one meetings with registered investors and other attendees throughout the conference. Those interested in scheduling a meeting with Processa management are encouraged to do so through the BIO Partnering <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0qkHo2JnsUup2R6hlVtreuR192KhSrq7HApsfpu5qFDU0V1kFE8Nlq9H9lPFiOdyyk5OYgBEcuId_0Gbn8PucVkzSsghquknWXn7kTZou-Hj10phB7Ah6ZmCk7SPD2EvifRN9jvFZVrynb9AvK1n1U_LrzPwNBmCtPIbokjKSp7jy9StwZrhkG1ZGVwu_9pFbYD3_o7Eq0B0yJAAmPtWspIC9bx2KhvOEKSQdxPUKgD5s3W-4m6P9FGOvy4gCMlIxGi6mvwJ_t4xGiQefPCqTMoPbHBa8TqBfsFKvYRcanlF164ajY4YmwO4kYlNTVrwufzuZS2Pt5FTOn22PHwZv8rm56yoHYFioJBRjgERPWUoTUq-9hSBf68Pf9SkxgoR3U7v0kr96iDyyUMkK45y9db9_FS6QEy0ZUsvHbMZTficSRTT8VFgWohjhFNZ1Q-8m8mTYH1YkmUAAJbtDHNTkTJoA-7k7hii2ANNyYAhuBnp-Z1l_4iH6_PYmKFEAKPjrbCeCx-72qjxt6cLBunWCRGlqXJwHVuVYeWmSK9OMITNVHVcfdmDlXGISKw2dBAgjdxDdoPGlm28ryBFPTu6cWIYySZlfDp_8tuIQHG0m6rNfFWoM0Jk9I_ve3NahGsIkw_SMOekM81TSkmUVQKO9yXxGjMVrRjv9QrAL2pj5waviMG5avVeT-SomDvtTwYWfQodAX7K6EFU6J9E_YFqROS9UjkdVuW1QohzCqppu5Rq_vowjVbzob561YcY2D_fBLyoMhC43hB3NCGnRMSwbp1Ev-7F27wesMH7EfnaoAe0AHd016WoAlwfn0rbGMBj8b9aTXist2lydz6Yb4z3_FrHO6Z4mcTtaVevfDpWumkFv-AfAFTuQAelNTFAZDh9sG39Fq5JTDq7FLH3PiIBuZONU4MYmtfsVr6bRnGXErIdQmKMvvg8m8uu8ZalT6VC-lUDmQqkLP_QrsLWxTHgIgtJKlKme7r9dEuXVJXSddg=\" rel=\"nofollow\" target=\"_blank\"><u>portal<\/u><\/a>. For those not attending the conference who are interested in meeting with Processa management, please contact Yvonne Briggs at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Sq1LXJmYczcaYID7zeS4cMx9QyelMBX5Wk50SinvPzJ6hyX8NCJfw_93NO_Xfu5d2fkg_d7ZVyL4qK6rryGv-dj17w6Kusm-fOZHwL-utKNHKlMDLWqtuTnTgCrQAVEw\" rel=\"nofollow\" target=\"_blank\"><u>ybriggs@allianceadvisors.com<\/u><\/a><u>.<\/u><\/p>\n<p align=\"justify\">\n        <strong>About\u00a0Processa\u00a0Pharmaceuticals, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy. Processa\u2019s NGC drugs are modifications of existing FDA-approved oncology therapies resulting in an alteration of the metabolism and\/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa\u2019s strategy is to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path.<\/p>\n<p align=\"justify\">For more information, visit our website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xu1nDXGo1mTa2SIYYlvldGrZFS3MtCbmzHm-AZVP68fEMqbcDEoGHwMxpFQ9cQE86hPoufpt4CswZFgpPc2WfG7ygLWLQuMfSa2HHftED_E=\" rel=\"nofollow\" target=\"_blank\"><u>www.processapharma.com<\/u><\/a><u>.<\/u><\/p>\n<p align=\"justify\">\n        <strong>Company\u00a0Contact:<\/strong><br \/>\n        <br \/>Patrick Lin<br \/>(925) 683-3218<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HId1OPET_JT8viCqNRAcheh26lOvVxUWHZH3PDNrMh9Xwsqzg1rIAwy6p_vSJ62u6jsVthaejdSZKrRQuQPN84S5sfb42Jfn_m7owh5Hh30=\" rel=\"nofollow\" target=\"_blank\"><u>plin@processapharma.com<\/u><\/a><\/p>\n<p align=\"justify\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>Yvonne Briggs<br \/>Alliance Advisors IR<br \/>(310) 691-7100<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Sq1LXJmYczcaYID7zeS4cMx9QyelMBX5Wk50SinvPzLfb6DnaJOn4O7rC7jGiUM-tJZwv_S-SP6ITIJr3aCYo2GhhXT1GP7_Cs3mmGTGZa56f_XEDaaFPzvCVf39vic5\" rel=\"nofollow\" target=\"_blank\"><u>ybriggs@allianceadvisors.com<\/u><\/a><\/p>\n<p align=\"center\"># # #<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDU5NCM2NzQwMjEyIzUwMDA0NjUzNQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YjI0YzYzODEtZWEyYy00NWNmLWJjMWYtMjhjZDZmMGVlODczLTUwMDA0NjUzNQ==\/tiny\/Processa-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) &#8212; Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced its participation in the 2025 BIO CEO &amp; Investor Conference being held February 10-11, 2025, at the New York Marriott Marquis. Management will present a corporate overview on Tuesday, February 11 at 10:00 a.m. Eastern time in the Plymouth Room, and will hold one-on-one meetings with registered investors and other attendees throughout the conference. Those interested in scheduling a meeting with Processa management are encouraged to do so through the BIO Partnering portal. For those not attending the conference who are interested in meeting &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Processa Pharmaceuticals to Present at the 2025 BIO CEO &amp; Investor Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-810435","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Processa Pharmaceuticals to Present at the 2025 BIO CEO &amp; Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Processa Pharmaceuticals to Present at the 2025 BIO CEO &amp; Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) &#8212; Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced its participation in the 2025 BIO CEO &amp; Investor Conference being held February 10-11, 2025, at the New York Marriott Marquis. Management will present a corporate overview on Tuesday, February 11 at 10:00 a.m. Eastern time in the Plymouth Room, and will hold one-on-one meetings with registered investors and other attendees throughout the conference. Those interested in scheduling a meeting with Processa management are encouraged to do so through the BIO Partnering portal. For those not attending the conference who are interested in meeting &hellip; Continue reading &quot;Processa Pharmaceuticals to Present at the 2025 BIO CEO &amp; Investor Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-07T13:04:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDU5NCM2NzQwMjEyIzUwMDA0NjUzNQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Processa Pharmaceuticals to Present at the 2025 BIO CEO &amp; Investor Conference\",\"datePublished\":\"2025-02-07T13:04:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\\\/\"},\"wordCount\":261,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NDU5NCM2NzQwMjEyIzUwMDA0NjUzNQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\\\/\",\"name\":\"Processa Pharmaceuticals to Present at the 2025 BIO CEO &amp; Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NDU5NCM2NzQwMjEyIzUwMDA0NjUzNQ==\",\"datePublished\":\"2025-02-07T13:04:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NDU5NCM2NzQwMjEyIzUwMDA0NjUzNQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NDU5NCM2NzQwMjEyIzUwMDA0NjUzNQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Processa Pharmaceuticals to Present at the 2025 BIO CEO &amp; Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Processa Pharmaceuticals to Present at the 2025 BIO CEO &amp; Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"Processa Pharmaceuticals to Present at the 2025 BIO CEO &amp; Investor Conference - Market Newsdesk","og_description":"HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) &#8212; Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced its participation in the 2025 BIO CEO &amp; Investor Conference being held February 10-11, 2025, at the New York Marriott Marquis. Management will present a corporate overview on Tuesday, February 11 at 10:00 a.m. Eastern time in the Plymouth Room, and will hold one-on-one meetings with registered investors and other attendees throughout the conference. Those interested in scheduling a meeting with Processa management are encouraged to do so through the BIO Partnering portal. For those not attending the conference who are interested in meeting &hellip; Continue reading \"Processa Pharmaceuticals to Present at the 2025 BIO CEO &amp; Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-07T13:04:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDU5NCM2NzQwMjEyIzUwMDA0NjUzNQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Processa Pharmaceuticals to Present at the 2025 BIO CEO &amp; Investor Conference","datePublished":"2025-02-07T13:04:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\/"},"wordCount":261,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDU5NCM2NzQwMjEyIzUwMDA0NjUzNQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\/","name":"Processa Pharmaceuticals to Present at the 2025 BIO CEO &amp; Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDU5NCM2NzQwMjEyIzUwMDA0NjUzNQ==","datePublished":"2025-02-07T13:04:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDU5NCM2NzQwMjEyIzUwMDA0NjUzNQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDU5NCM2NzQwMjEyIzUwMDA0NjUzNQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-present-at-the-2025-bio-ceo-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Processa Pharmaceuticals to Present at the 2025 BIO CEO &amp; Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/810435","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=810435"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/810435\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=810435"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=810435"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=810435"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}